NIFEdipine ER

ApprovedSmall molecule

MMedical College of Wisconsin

NIFEdipine ER is one of 41 small molecule programs targeting Primary Aldosteronism. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary AldosteronismActive, not recruiting

HypertensionActive, not recruiting

Primary AldosteronismPreclinical

Active, not recruiting

HypertensionApproved

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

NIFEdipine ER

MMedical College of Wisconsin

Approved

4 2

Edarbi

Takeda

Preclinical

10 3

Apresoline

Novartis

Preclinical

7 4

Benicar

Novartis

Preclinical

7 5

Edarbi

Takeda

Preclinical

4 6

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 7

Alphagan

Winrevair

Disalcid

JJoslin Diabetes Center

Preclinical

1 10

Avastin

BBio-Thera Solutions

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

N/ARecruiting

Hypertension

NCT06220721

Clinical

Trials by Indication[1]

Hypertension4 trials

Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT05049616·70 enrolled

Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia

Recruiting·MMedical College of Wisconsin·N/A·NCT06220721·618 enrolled

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

Recruiting·NNebraska Methodist Health System·Phase 4·NCT05309460·600 enrolled

Show 1 more trial

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

Completed·PPrisma Health-Upstate·Phase 4·NCT04790279·175 enrolled

Postpartum Period1 trial

Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period

Completed·—·Phase 4·NCT04236258·94 enrolled

Hypertensive1 trial

Intensive Postpartum Antihypertensive Treatment

Active, not recruiting·MMedical College of Wisconsin·Phase 3·NCT05687344·60 enrolled

Primary Aldosteronism1 trial

Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism

Completed·QQueen Mary University of London·N/A·NCT05686993·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for NIFEdipine ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NIFEdipine ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NIFEdipine ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical College of Wisconsin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMedical College of Wisconsin

NIFEdipine ER

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Hypertension4 trials

Postpartum Period1 trial

Hypertensive1 trial

Primary Aldosteronism1 trial

References

Drug Info

Quick Facts

Related News